Family Medicine Doctors in Dededo, GU Accepting Medicare

9 Family Medicine doctors found. Showing 1 - 9

Dr. Maria Chela Arana Mariano, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 330 W Marine Corps Dr, Dededo, GU 96929 Phone: 671-637-8112    Fax: 671-637-8113

Dawn Dee Ostberg, FNP-BC Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4404    Fax: 671-633-4452

Dr. Edna Ganacias-acuna, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Route 3, Dededo, GU 96929 Phone: 671-645-5500    Fax: 671-645-5549

Luis G Cruz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4447    Fax: 671-633-4452

Hieu T Campus, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Road, Ste. 108, Dededo, GU 96929 Phone: 671-633-4447    Fax: 671-633-4452

Delores Johanne Lee, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4447

Dr. Arania Oceanis Adolphson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4447

Dr. Edmund Schroeder Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 300, Dededo, GU 96929 Phone: 671-647-5355    Fax: 671-647-5358

Dr. Chris Curran Dombrowski, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2214 Army Dr, Dededo, GU 96929 Phone: 671-637-1777    Fax: 671-637-4385

News Archive

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

Viewpoints: Where is the surgeon general; Unions' health law waivers; Mass. plan to aid municipalities

Although some of the nation's healthcare issues are abstruse and vexing, others are relatively approachable. Many in this latter category fall within the province of the U.S. surgeon general. But the incumbent is nowhere to be found.

Patients taking the lipid-lowering medications have a relatively low risk of developing rhabdomyolysis

Patients taking the lipid-lowering medications atorvastatin, pravastatin, and simvastatin to reduce cholesterol levels, have a relatively low risk of developing rhabdomyolysis, (a disorder that causes the breakdown of muscle), according to a new study in the December 1 issue of JAMA.

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.

Read more Medical News

› Verified 4 days ago